Hyperkalemia

Hyperkalemia is a potentially life-threatening electrolyte disturbance characterized by an elevated serum potassium concentration above the reference interval for the species. In dogs and cats, the normal serum potassium concentration typically ranges from 3.5 to 5.5 mEq/L (or mmol/L), with slight variations between laboratories. Hyperkalemia is defined as a serum potassium concentration exceeding 5.5 mEq/L in most clinical settings. The severity is often categorized as mild (5.5–6.0 mEq/L), moderate (6.1–7.0 mEq/L), or severe (>7.0 mEq/L), with severe hyperkalemia posing an imminent risk of cardiac arrhythmias and cardiac arrest. Potassium is the primary intracellular cation, and its distribution across cell membranes is critical for maintaining the resting membrane potential of excitable tissues, including cardiac and skeletal muscle. The clinical consequences of hyperkalemia are primarily related to alterations in neuromuscular excitability, particularly affecting the myocardium, leading to characteristic electrocardiographic (ECG) changes and potentially fatal arrhythmias. Hyperkalemia is not a primary disease but rather a clinicopathological abnormality that arises from a variety of underlying disorders, including decreased renal excretion, increased endogenous or exogenous potassium load, and shifts of potassium from the intracellular to the extracellular space. Prompt recognition and management are essential to prevent life-threatening complications.

The etiologies of hyperkalemia can be broadly classified into three pathophysiological categories: (1) decreased renal potassium excretion, (2) increased potassium intake or load, and (3) transcellular shifts of potassium from the intracellular to the extracellular compartment. Decreased renal excretion is the most common cause in veterinary patients and is often due to acute or chronic kidney disease, particularly oliguric or anuric acute kidney injury (AKI), and chronic kidney disease (CKD) in advanced stages (IRIS stage 3 and 4). Urethral obstruction, ruptured urinary bladder, or other causes of post-renal azotemia can also lead to hyperkalemia due to impaired excretion. Hypoadrenocorticism (Addison's disease) is a classic endocrine cause, where deficiency of aldosterone leads to decreased renal potassium secretion and impaired sodium reabsorption. Other causes of hypoaldosteronism include iatrogenic (e.g., administration of certain drugs) or primary hypoaldosteronism. Gastrointestinal disease with severe vomiting or diarrhea can cause metabolic acidosis and subsequent transcellular shifts, but this is less common. Increased potassium load can result from iatrogenic administration of potassium-containing fluids, excessive dietary intake (rare in animals), or massive tissue breakdown (e.g., tumor lysis syndrome, rhabdomyolysis, hemolysis). Transcellular shifts can be induced by metabolic acidosis (especially mineral acidosis), insulin deficiency (diabetic ketoacidosis), beta-adrenergic blockade, and drugs such as digoxin overdose or succinylcholine. In addition, certain breeds may have a genetic predisposition to hyperkalemia, such as the hyperkalemic periodic paralysis in affected breeds, though this is rare in veterinary medicine.

Hyperkalemia is a common electrolyte abnormality encountered in small animal practice, particularly in emergency and critical care settings. The exact incidence is not well-documented, but it is frequently observed in cats with urethral obstruction, which is a common emergency in male cats. In dogs, hyperkalemia is often associated with hypoadrenocorticism, acute kidney injury, and urinary tract obstruction. There is no strong breed or sex predilection for hyperkalemia per se, but the underlying causes may have breed predispositions. For example, hypoadrenocorticism is more common in young to middle-aged female dogs, with certain breeds such as Standard Poodles, Bearded Collies, and Portuguese Water Dogs being overrepresented. Urethral obstruction is predominantly seen in male cats, especially neutered males, and can occur at any age but is more common in middle-aged cats. Chronic kidney disease is more prevalent in older cats and dogs, and hyperkalemia is more likely in advanced stages. Geographic and seasonal variations may influence the incidence of certain causes, such as ethylene glycol toxicity (a cause of AKI) being more common in colder months. Overall, hyperkalemia is a significant clinical problem that requires prompt recognition and management to reduce morbidity and mortality.

Potassium homeostasis is maintained by the balance between dietary intake, cellular distribution, and renal excretion. The Na+/K+-ATPase pump actively transports potassium into cells, while insulin and beta-adrenergic agonists promote cellular uptake. Aldosterone enhances renal potassium secretion in the distal tubules and collecting ducts. Hyperkalemia develops when any of these regulatory mechanisms are disrupted. Decreased renal excretion occurs when there is reduced glomerular filtration rate (GFR) or impaired tubular secretion, as seen in AKI, CKD, or hypoaldosteronism. In urethral obstruction, the backpressure on the kidneys reduces GFR and also causes tubular damage, leading to decreased potassium excretion. Increased potassium load can overwhelm the excretory capacity, especially if renal function is compromised. Transcellular shifts occur when potassium moves out of cells into the extracellular fluid, often due to acidosis (hydrogen ions enter cells, displacing potassium), insulin deficiency, or beta-blockade. The most dangerous consequence of hyperkalemia is its effect on the resting membrane potential of cardiac myocytes. Elevated extracellular potassium reduces the potassium gradient across the cell membrane, leading to depolarization of the resting membrane potential. This initially increases excitability but then inactivates sodium channels, slowing conduction and altering repolarization. The ECG changes progress from tall, peaked T waves (early), to prolonged PR interval and widened QRS complex (moderate), and eventually to sine wave pattern and ventricular fibrillation or asystole (severe). Hyperkalemia also affects skeletal muscle, causing weakness and flaccid paralysis, and can impair renal function further by reducing renal blood flow and GFR.

Several factors can predispose an animal to hyperkalemia. Intrinsic factors include age (older animals are more prone to CKD), breed (certain breeds are predisposed to hypoadrenocorticism or urinary obstruction), and sex (male cats are at higher risk for urethral obstruction). Genetic factors may play a role in some cases, such as familial hypoadrenocorticism in certain breeds. Extrinsic factors include dietary potassium excess (rare), iatrogenic administration of potassium-containing fluids or potassium-sparing diuretics (e.g., spironolactone), and concurrent use of medications that impair renal potassium excretion, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or ACE inhibitors. Concurrent diseases that cause metabolic acidosis, such as diabetic ketoacidosis or severe diarrhea, can precipitate transcellular shifts. Urinary tract obstruction, whether due to urolithiasis, neoplasia, or stricture, is a major predisposing factor. Trauma or surgery leading to tissue ischemia or reperfusion injury can cause potassium release from damaged cells. In critically ill patients, factors such as hypovolemia, hypotension, and sepsis can reduce renal perfusion and impair potassium excretion. Additionally, certain endocrine disorders, such as hypoadrenocorticism, directly predispose to hyperkalemia due to aldosterone deficiency.

The clinical signs of hyperkalemia are primarily related to neuromuscular and cardiac dysfunction. Early signs may be nonspecific and include weakness, lethargy, and anorexia. As hyperkalemia progresses, more specific signs may develop. In the neuromuscular system, muscle weakness can progress to flaccid paralysis, particularly in the limbs. Gastrointestinal signs such as vomiting and diarrhea may be present, especially if the underlying cause is gastrointestinal disease. Cardiovascular signs are the most concerning and include bradycardia, irregular heart rhythm, and potentially cardiac arrest. On physical examination, the animal may appear depressed, have a weak pulse, and may exhibit hypothermia. In cases of urethral obstruction, there will be signs of dysuria, stranguria, or anuria, and the bladder may be distended and painful on palpation. In hypoadrenocorticism, additional signs may include polyuria/polydipsia, dehydration, and gastrointestinal signs. The severity of clinical signs correlates with the degree and rapidity of onset of hyperkalemia. Chronic hyperkalemia may be better tolerated than acute hyperkalemia, but any potassium concentration above 7.0 mEq/L is considered a medical emergency. Electrocardiographic changes may be present even in the absence of clinical signs, so ECG monitoring is essential in any patient with suspected hyperkalemia.

The differential diagnoses for hyperkalemia include: (1) Acute kidney injury (AKI) – characterized by sudden onset of azotemia, oliguria or anuria, and often associated with toxins (e.g., ethylene glycol), ischemia, or sepsis. (2) Chronic kidney disease (CKD) – typically in older animals with a history of weight loss, polyuria/polydipsia, and nonregenerative anemia; hyperkalemia is more common in advanced stages. (3) Urethral obstruction – common in male cats, presenting with dysuria, anuria, and a palpable distended bladder; often accompanied by azotemia and hyperkalemia. (4) Hypoadrenocorticism (Addison's disease) – classic findings include hyponatremia, hyperkalemia, and a sodium-to-potassium ratio <27:1; may also have hypoglycemia, and the animal may be in shock. (5) Diabetic ketoacidosis – hyperglycemia, ketonemia, metabolic acidosis, and often hyperkalemia due to insulin deficiency and acidosis. (6) Severe metabolic acidosis from other causes (e.g., diarrhea, renal tubular acidosis) – can cause transcellular shifts. (7) Iatrogenic – excessive potassium supplementation, potassium-sparing diuretics, or ACE inhibitors. (8) Tumor lysis syndrome – rare but can occur after chemotherapy for rapidly dividing tumors. (9) Rhabdomyolysis or severe tissue trauma – release of intracellular potassium. (10) Pseudohyperkalemia – due to hemolysis during blood sampling or prolonged contact with red blood cells, especially in certain breeds (e.g., Akita, Japanese breeds) with high red blood cell potassium content. Each differential can be differentiated by history, physical examination, and specific laboratory tests.

The diagnostic approach to hyperkalemia should be systematic and urgent. First, confirm the hyperkalemia with a serum biochemistry panel, but be aware of pseudohyperkalemia due to hemolysis or delayed separation. If the potassium is elevated, immediately assess the patient's cardiovascular status with an ECG. If ECG changes are present, treat the hyperkalemia emergently while continuing the diagnostic workup. Next, obtain a thorough history and physical examination, focusing on urinary tract signs, medication history, and possible toxin exposure. Perform a complete blood count, serum biochemistry profile, and urinalysis. The biochemistry profile should include electrolytes (sodium, chloride, calcium, phosphorus), blood urea nitrogen (BUN), creatinine, glucose, and total CO2 or blood gas analysis. A urinalysis is crucial to assess urine specific gravity, sediment, and the presence of casts or crystals. If the animal is azotemic, determine if the azotemia is renal, pre-renal, or post-renal by assessing hydration status and urine output. If post-renal obstruction is suspected, perform abdominal imaging (radiography or ultrasound) to evaluate the bladder and urethra. If hypoadrenocorticism is suspected, measure baseline cortisol and perform an ACTH stimulation test. Additional tests may include serum fructosamine for diabetes, blood gas analysis for acidosis, and measurement of lactate. In cases of suspected ethylene glycol toxicity, a specific test may be available. The diagnostic algorithm should be tailored to the most likely underlying cause based on signalment and clinical signs.

Laboratory findings in hyperkalemia include an elevated serum potassium concentration (>5.5 mEq/L). Other electrolyte abnormalities may be present depending on the underlying cause. In hypoadrenocorticism, hyponatremia and hyperkalemia are classic, with a sodium-to-potassium ratio often less than 27:1. In renal disease, there may be azotemia (elevated BUN and creatinine), hyperphosphatemia, and metabolic acidosis. In urethral obstruction, there is often azotemia, hyperkalemia, hyperphosphatemia, and metabolic acidosis. In diabetic ketoacidosis, hyperglycemia, ketonemia, and metabolic acidosis are present. Hematology may show a stress leukogram or hemoconcentration. Urinalysis may reveal isosthenuria (USG <1.030 in dogs, <1.035 in cats) in renal disease, or the presence of crystals (e.g., struvite or calcium oxalate) in obstructive disease. Blood gas analysis may show metabolic acidosis. Additional biomarkers such as SDMA (symmetric dimethylarginine) may be elevated in renal disease. In cases of suspected hypoadrenocorticism, baseline cortisol is low and fails to increase after ACTH stimulation. In ethylene glycol toxicity, calcium oxalate crystals may be seen in the urine, and an elevated osmolal gap may be present.

Imaging studies are essential in the diagnostic workup of hyperkalemia, particularly to identify underlying causes such as urinary tract obstruction or renal disease. Abdominal radiography can reveal radiopaque uroliths, a distended bladder, or loss of abdominal detail suggestive of a ruptured bladder. Ultrasonography is more sensitive for detecting uroliths, assessing renal size and architecture, and evaluating the bladder wall. In cases of urethral obstruction, ultrasound can confirm the presence of a distended bladder and may identify the cause (e.g., urolith, mass). In chronic kidney disease, ultrasound may show small, irregular kidneys with increased echogenicity. In acute kidney injury, kidneys may be enlarged and hyperechoic. Thoracic radiography may be indicated if there is suspicion of metastatic disease or other thoracic pathology. Echocardiography is not routinely performed for hyperkalemia itself but may be indicated if cardiac disease is suspected. Advanced imaging such as CT or MRI is rarely needed but may be useful in specific cases, such as suspected adrenal mass causing hypoadrenocorticism (though this is rare).

Cytology and histopathology are not typically required for the diagnosis of hyperkalemia itself, but they may be indicated to diagnose the underlying cause. For example, if a mass is detected in the urinary tract, fine-needle aspiration or biopsy may be performed. In cases of suspected hypoadrenocorticism, adrenal histopathology is rarely performed, but if an adrenal mass is found, cytology or biopsy may be considered. In renal disease, renal biopsy may be indicated to differentiate between different types of glomerulonephritis or interstitial nephritis, but this is usually reserved for cases where the diagnosis is unclear and the results would alter treatment. Histopathological findings in renal disease may include glomerular changes, tubular necrosis, interstitial fibrosis, or inflammation. In ethylene glycol toxicity, renal histopathology may show calcium oxalate crystals in the tubules. However, in most cases of hyperkalemia, the diagnosis is made based on clinical signs, laboratory tests, and imaging, and invasive procedures are not necessary.

The treatment of hyperkalemia depends on the severity and underlying cause. Emergency treatment is indicated for severe hyperkalemia (potassium >7.0 mEq/L) or when ECG changes are present. The goals are to stabilize the myocardium, shift potassium into cells, and remove potassium from the body. First-line therapy includes intravenous calcium gluconate (10% solution) at a dose of 0.5-1.0 mL/kg (50-100 mg/kg) given slowly over 10-20 minutes with ECG monitoring. Calcium does not lower potassium but antagonizes its effects on the myocardium. Next, to shift potassium intracellularly, administer regular insulin (0.1-0.2 U/kg IV) followed by dextrose (2 g per unit of insulin) to prevent hypoglycemia. Alternatively, dextrose alone (0.5-1 g/kg IV) can stimulate endogenous insulin release. Sodium bicarbonate (1-2 mEq/kg IV over 15-30 minutes) can be used if metabolic acidosis is present, but its use is controversial and should be reserved for severe acidosis. Beta-2 agonists such as albuterol can also promote cellular uptake but are less commonly used in veterinary medicine. To remove potassium from the body, loop diuretics (e.g., furosemide 1-2 mg/kg IV) or thiazide diuretics may be used if renal function is adequate. In oliguric or anuric patients, dialysis (hemodialysis or peritoneal dialysis) may be necessary. For underlying causes, specific treatments are required: for urethral obstruction, relieve the obstruction via catheterization or cystocentesis; for hypoadrenocorticism, administer mineralocorticoid replacement (e.g., desoxycorticosterone pivalate or fludrocortisone) and glucocorticoids; for renal disease, manage with fluid therapy, dietary modification, and supportive care. Fluid therapy with 0.9% saline is often recommended because it does not contain potassium and can help dilute extracellular potassium. Avoid potassium-containing fluids. In all cases, continuous ECG monitoring is essential during treatment.

The prognosis for hyperkalemia depends on the underlying cause, the severity of the potassium elevation, and the promptness of treatment. If hyperkalemia is detected early and treated aggressively, the prognosis can be good, especially if the underlying cause is reversible, such as urethral obstruction or iatrogenic potassium overload. However, if hyperkalemia is severe and leads to cardiac arrest, the prognosis is grave. In cases of acute kidney injury, the prognosis is guarded to poor, especially if oliguric or anuric. Chronic kidney disease with hyperkalemia indicates advanced disease, and the long-term prognosis is poor, though management can prolong survival. Hypoadrenocorticism has a good prognosis with appropriate lifelong treatment. Urethral obstruction in cats has a good prognosis if treated promptly, but recurrence is common. The presence of ECG changes, particularly wide QRS complexes or sine wave pattern, indicates severe hyperkalemia and a worse prognosis. Negative prognostic indicators include severe azotemia, oliguria, and lack of response to initial therapy. Overall, the prognosis is highly variable and must be assessed on a case-by-case basis.

Follow-up care for hyperkalemia depends on the underlying cause. After initial stabilization, serum potassium should be rechecked frequently (e.g., every 4-6 hours) until it normalizes. Once the patient is stable, the underlying disease must be managed. For urethral obstruction, the urinary catheter is typically left in place for 24-48 hours, and the patient is monitored for urine output and resolution of azotemia. For hypoadrenocorticism, lifelong mineralocorticoid and glucocorticoid therapy is required, with regular monitoring of electrolytes (initially weekly, then monthly or as needed). For chronic kidney disease, regular monitoring of renal parameters (BUN, creatinine, SDMA, electrolytes) and blood pressure is recommended, with adjustments to diet and medications as needed. For acute kidney injury, follow-up may include serial renal function tests and blood pressure monitoring. In all cases, owners should be educated on the signs of hyperkalemia and the importance of regular veterinary check-ups. The frequency of rechecks should be tailored to the individual patient's condition and response to treatment.

Pearls: 1) Always confirm hyperkalemia with a serum biochemistry panel, but be aware of pseudohyperkalemia due to hemolysis or delayed separation, especially in breeds like Akitas. 2) ECG changes are not always present, but if they are, treat immediately. 3) Calcium gluconate is the first-line treatment for cardiac protection, but it does not lower potassium. 4) Insulin and dextrose are effective for shifting potassium into cells, but monitor for hypoglycemia. 5) In any azotemic animal with hyperkalemia, consider urethral obstruction, especially in male cats. 6) A sodium-to-potassium ratio <27:1 is highly suggestive of hypoadrenocorticism. 7) Always check a baseline cortisol before starting glucocorticoid therapy if hypoadrenocorticism is suspected. Pitfalls: 1) Do not administer calcium gluconate if hypercalcemia is present. 2) Do not use sodium bicarbonate routinely; it can cause paradoxical intracellular acidosis and hypocalcemia. 3) Avoid potassium-containing fluids (e.g., Lactated Ringer's) in hyperkalemic patients. 4) Do not delay treatment while waiting for diagnostic tests if ECG changes are present. 5) Do not forget to monitor blood glucose after insulin administration. 6) Do not overlook the possibility of a ruptured bladder in a cat with anuria and hyperkalemia. 7) Do not use potassium-sparing diuretics (e.g., spironolactone) in hyperkalemic patients.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for hyperkalemia: 1) Calcium gluconate 10% solution: 0.5-1.0 mL/kg (50-100 mg/kg) IV over 10-20 minutes with ECG monitoring; can be repeated if needed. 2) Regular insulin: 0.1-0.2 U/kg IV, followed by dextrose 2 g per unit of insulin (typically 0.5-1 g/kg IV) to prevent hypoglycemia. 3) Dextrose alone: 0.5-1 g/kg IV as a 20% or 50% solution. 4) Sodium bicarbonate: 1-2 mEq/kg IV over 15-30 minutes, only if severe metabolic acidosis (pH <7.1) is present. 5) Furosemide: 1-2 mg/kg IV or IM, q8-12h, to promote diuresis if renal function is adequate. 6) Albuterol: 0.5 mg/kg PO (or 2 puffs of inhaler) can be used, but is not commonly used in veterinary medicine. 7) For hypoadrenocorticism: Desoxycorticosterone pivalate (DOCP) 2.2 mg/kg IM or SC every 25 days, or fludrocortisone acetate 0.01-0.02 mg/kg/day PO, and prednisone 0.2-0.5 mg/kg/day PO. 8) For urethral obstruction: relieve obstruction, and consider fluid therapy with 0.9% saline. 9) For acute kidney injury: consider dialysis if refractory. All dosages should be adjusted based on renal and hepatic function, and contraindications should be considered. For example, calcium gluconate is contraindicated in hypercalcemia, and insulin should be used with caution in patients with hypoglycemia.

Evidence-based literature on hyperkalemia in veterinary medicine is limited, but several key studies and consensus guidelines exist. The ACVIM consensus statement on the diagnosis and management of acute kidney injury in dogs and cats (2016) provides recommendations for managing hyperkalemia in AKI, including the use of calcium gluconate, insulin/dextrose, and dialysis. The IRIS (International Renal Interest Society) guidelines for CKD staging and management also address hyperkalemia as a complication of advanced CKD. Studies on urethral obstruction in cats have shown that hyperkalemia is a common finding and is associated with increased risk of arrhythmias and death. A study by Lee et al. (2012) reported that cats with urethral obstruction and potassium >7.0 mEq/L had a higher mortality rate. Research on hypoadrenocorticism has established the diagnostic criteria and treatment protocols, with studies showing that DOCP is effective for long-term management. There is also evidence that pseudohyperkalemia can occur in certain breeds, such as Akitas, due to high red blood cell potassium content. Overall, the management of hyperkalemia is largely based on extrapolation from human medicine and expert opinion, but the principles of treatment are well-established. Further research is needed to evaluate the optimal protocols for potassium-lowering therapy in veterinary patients.